Pacific Edge posts $14.5m loss as it awaits US Medicare decisions

Pacific Edge posts $14.5m loss as it awaits US Medicare decisions
Pacific Edge chief executive Peter Meintjes says as each day passes, he feels more confident about a favourable decision from Novitas. (Image: Supplied)
John Anthony
Dunedin-headquartered cancer diagnostics company Pacific Edge has posted a $14.5 million after-tax loss for the six months to September 30.The NZX and ASX-listed company said it was awaiting outcomes of several events that had the potential to renew growth in Cxbladder, its urine-based genomic biomarker test for the detection and surveillance of bladder cancer. The events include:Novitas, the Medicare Administrative Contractor (MAC) with responsibility for Pacific Edge’s US lab, making a favourable policy decision on a Local Coverage...

More Markets

NZ stocks end flat amid Fletcher-SkyCity legal woes
Markets Market Close

NZ stocks end flat amid Fletcher-SkyCity legal woes

Tesla's 14% drop again highlighted the general state of global market uncertainty.

Jamie Gray 06 Jun 2025
SkyCity claims it is entitled to $330m in damages from Fletcher Building
Markets

SkyCity claims it is entitled to $330m in damages from Fletcher Building

The original delivery date of the International Convention Centre was January 2019. 

Rebecca Howard 06 Jun 2025
10 NZ firms could get slice of $200m Fisher KiwiSaver cash
Markets

10 NZ firms could get slice of $200m Fisher KiwiSaver cash

Private equity investing will benefit both KiwiSavers and business, fund manager says.